This is the first study to demonstrate a tumor suppressive role for LRRK2 in carcinogen-induced distal lung cancer, and to potentially identify a Parkinson’s patient population (i.e. current smokers) for whom long-term LRRK2 inhibition may require additional monitoring. This evidence concerns the gene LRRK2 and neoplasm.